Concordance of DMET plus genotyping results with those of orthogonal genotyping methods

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 3, 2012, Pages 360-365

  Fernandez, C A ^a   Smith, C ^a   Yang, W ^a   Lorier, R ^b   Crews, K R ^a   Kornegay, N ^a   Hicks, J K ^a   Stewart, C F ^a   Kawedia, J D ^a   Ramsey, L B ^a   Liu, C ^a   Evans, W E ^a   Relling, M V ^a   Broeckel, U ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLIZING ENZYME; DRUG METABOLIZING ENZYME AND TRANSPORTER; UNCLASSIFIED DRUG;

ABCB1 GENE; ABCC4 GENE; ARTICLE; CYP1B1 GENE; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; CYP3A5 GENE; DPYD GENE; FEMALE; FMO3 GENE; GENE; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NQO1 GENE; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B1 GENE; TPMT GENE; UGT1A1 GENE; VKORC1 GENE;

CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENES; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84865431148     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.95     Document Type: Article

References (21)

1. Evans, W.E. & McLeod, H.L Pharmacogenomics-drug disposition, drug targets, and side efects. N. Engl. J. Med. 348, 538-549 (2003).
2. Kalow, W., Tang, B.K. & Endrenyi, L. Hypothesis: comparisons of inter-and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 8, 283-289 (1998). (Pubitemid 28372321)
3. Dervieux, T., Meshkin, B. & Neri, B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat. Res. 573, 180-194 (2005).
4. Sakurai, A., Tamura, A., Onishi, Y. & Ishikawa, T. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications. Expert Opin. Pharmacother. 6, 2455-2473 (2005). (Pubitemid 41701048)
5. Deeken, J. The Afymetrix DMET platform and pharmacogenetics in drug development. Curr. Opin. Mol. Ther. 11, 260-268 (2009).
6. Afymetrix. DMET™ Plus Premier Pack allele translation reports: Summary of comprehensive drug disposition genotyping into commonly recognized allele names http://media.afymetrix.com/support/technical/whitepapers/dmet-plus- translation.pdf (2011).
7. Dumaual, C et al. Comprehensive assessment of metabolic enzyme and transporter genes using the Afymetrix Targeted Genotyping System. Pharmacogenomics 8, 293-305 (2007). (Pubitemid 46477741)
8. Sissung, T.M., English, B.C., Venzon, D., Figg, W.D. & Deeken, J.F. Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics 11, 89-103 (2010).
9. Afymetrix. DMET™ Plus genotyping and copy number methods http://media.afymetrix.com/support/technical/whitepapers/dmet-plus-algorithm- whitepaperv1.pdf (2011).
10. Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464-467 (2011).
11. Daly, T.M. et al. Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport. Clin. Chem. 53, 1222-1230 (2007). (Pubitemid 47020977)
12. Deeken, J.F. et al. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J. 10, 191-199 (2010).
13. Burmester, J.K., Sedova, M., Shapero, M.H. & Mansfeld, E. DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol. Biol. 632, 99-124 (2010).
14. Warnes, G. & Leisch, F. Population Genetics. R package. 1.1.0 edn., (2004).
15. Yang, J.J. et al. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat. Genet. 43, 237-241 (2011).
16. Mansfeld, E. et al. Extensive population-based variation in drug metabolism is revealed by analyzing HapMap DNA with the Afymetrix® DMET™ Plus array [abstr.] http://media.afymetrix.com/community/events/ 2009-ashg/2009-ashg-pdfs/Variation-in-Drug-Metabolism-Revealed-by-DMET-Plus- Array.pdf (2009).
17. Treviño, L.R. et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat. Genet. 41, 1001-1005 (2009).
18. Shen, R. et al. High-throughput SNP genotyping on universal bead arrays. Mutat. Res. 573, 70-82 (2005). (Pubitemid 40514402)
19. Tantisira, K.G. et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum. Mol. Genet. 13, 1353-1359 (2004). (Pubitemid 38961642)
20. Jones, T.S. et al. CRHR1 polymorphisms predict bone density in survivors of acute lymphoblastic leukemia. J. Clin. Oncol. 26, 3031-3037 (2008).
21. French, D. et al.; Children's Oncology Group. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 111, 4496-4499 (2008).